Alters- und geschlechtsbedingte Unterschiede bei SVR und Rezidiven nach Therapie der HCV-Genotyp 3-(G3)-Infektion mit Peginterferon Alfa-2b (Peg2b)/Ribavirin (RBV) in der Praxis
S Mauss, D Hueppe, E Zehnter, MP Manns, G Teuber, T Dahhan, U Meyer, T Witthoeft, B Moeller, N Dikopoulos, J Brack, D Hartmann, A Heuser, M Bilzer · Zeitschrift für Gastroenterologie · 2012 · Heft 08
Bibliografische Angaben
Zusammenfassung
Aims: Because of the lack of new antiviral drugs, improvement of HCV G3 treatment can be achieved only by optimization of current standard therapy. Preliminary data suggest lower SVR rates for G3 infected elder patients. We therefore aimed to identify the contributing factors. Methods: Within a multicenter observational study in Germany 1328 of 4061 patients with chronic hepatitis C were infected with G3. Of these, 1090 patients had documented treatment with Peg-IFNα-2b 1.5µg/kg/wk plus RBV (800–1200mg/day) for a median of 24 weeks and were included in this retrospective analysis. Patients were stratified accord…
